MARKET

CRIS

CRIS

Curis
NASDAQ
0.6106
-0.0424
-6.49%
Opening 13:45 11/11 EST
OPEN
0.6390
PREV CLOSE
0.6530
HIGH
0.6609
LOW
0.5613
VOLUME
397.55K
TURNOVER
--
52 WEEK HIGH
28.40
52 WEEK LOW
0.3250
MARKET CAP
4.08M
P/E (TTM)
-0.0426
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (1102-1106)?
Weekly Report · 2d ago
Curis Faces Nasdaq Delisting Risk After Bid-Price Deficiency
TipRanks · 4d ago
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
Barchart · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/04 17:05
Dow Jumps Over 1,100 Points; McDonald’s Shares Gain Following Upbeat Earnings
Benzinga · 11/04 14:42
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/04 12:05
Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/04 09:47
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.